Clinical Significance of PAI-1 for Lacunar Infarction in Type 2 Diabetic Patients.

  • Satani Kahori
    Division of Diabetes and Metabolism, Department of Internal Medicine, Hyogo College of Medicine
  • Konya Hiroyuki
    Division of Diabetes and Metabolism, Department of Internal Medicine, Hyogo College of Medicine
  • Hasegawa Yoshikazu
    Division of Diabetes and Metabolism, Department of Internal Medicine, Hyogo College of Medicine
  • Hamaguchi Tomoya
    Division of Diabetes and Metabolism, Department of Internal Medicine, Hyogo College of Medicine
  • Kohri Kousuke
    Division of Diabetes and Metabolism, Department of Internal Medicine, Hyogo College of Medicine
  • Suehiro Akira
    Division of Diabetes and Metabolism, Department of Internal Medicine, Hyogo College of Medicine
  • Namba Mitsuyoshi
    Division of Diabetes and Metabolism, Department of Internal Medicine, Hyogo College of Medicine
  • Kakishita Eizo
    Division of Diabetes and Metabolism, Department of Internal Medicine, Hyogo College of Medicine

Bibliographic Information

Other Title
  • 2型糖尿病患者におけるラクナ梗塞危険因子としての血中PAI‐1濃度測定の意義
  • 2ガタ トウニョウビョウ カンジャ ニ オケル ラクナ コウソク キケン インシ ト シテ ノ ケッチュウ PAI-1 ノウド ソクテイ ノ イギ

Search this article

Abstract

We studied whether plasminogen activator inhibitor 1 (PAI-1) was a risk factor for lacunar infarction in type 2 diabetic patients. Although PAI-1 was not related to HbA1c concentrations and advanced glycation endproducts (AGEs) or fasting CPR, it was related significantly to the percent of body fat (%BF), body mass index (BMI) and average blood pressure. PAI-1 was also related to platelet count, fibrinogen level and the number of lacunar infarctions analyzed with brain magnetic resonance imaging (MRI). These results suggest that PAI-1 may be a risk factor for lacunar infarction by activating coagulation and inhibiting fibrinolysis in cerebrovascular lesions in type 2 diabetic patients.

Journal

References(18)*help

See more

Details 詳細情報について

Report a problem

Back to top